Abstract
AbstractEfforts in the pharmaceutical market have been aimed at ensuring that the benefits obtained from the introduction of new therapies justify the associated costs. In recent years, drug payment models in healthcare have undergone a dramatic shift from focusing on volume (i.e., size of the target clinical population) to focusing on value (i.e., drug performance in real-world settings). In this context, value-based contracts (VBCs) were designed to align the payment of a drug to its clinical performance outside clinical trials by evaluating the effectiveness using real-word evidence (RWE). Despite their widespread implementation, different factors jeopardize the application of VBCs to most marketed drugs in a near future, including the need for easily measurable and relevant outcomes associated with clinical improvements, and access to a large patient population to assess said outcomes. Here, we argue that the extraction and analysis of massive amounts of RWE captured in patients’ electronic health records (EHRs) will circumvent these issues and optimize negotiations in VBCs. Particularly, the use of Natural Language Processing (NLP) has proven successful in the analysis of structured and unstructured clinical information in EHRs in multicenter research studies. Thus, the application of NLP to analyze patient-centered information in EHRs in the context of innovative contracting can be utterly beneficial as it enables the real-time evaluation of treatment response and financial impact in real-world settings.
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. CatSalut. Guía para la definición de criterios de aplicación de esquemas de pago basados en resultados (EPR) en el ámbito farmacoterapéutico (acuerdos de riesgo compartido) Barcelona: Generalitat de Catalunya; 2014.
2. Braining G, Lynch M, Hayes K. Value-based agreements in healthcare: willingness versus ability. American Health & Drugs Benefits. 2019;12(5).
3. Kee A, Maio V. Value-based contracting: challenges and opportunities. Am J Med Qual. 2019;34(6):615–7.
4. Chatterjee A, Dougan C, Tevelow B, Zamani A. Innovative pharma contracts: When do value-based arrangements work? : McKinsey & Company; 2017.
5. Buyse M, Carter S, Sarnataro K. Factors influencing the implementation of value-based contracting between pharmaceutical manufacturers and payers. J Clin Pathways. 2018;4(4):27–30.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献